Corcept Therapeutics Shares Fall Again Amid Report FDA Warned Several Times Not to Submit Relacorilant Drug Application - Hagens Berman
Overall Survival Primary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
Corcept Therapeutics Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% - Hagens Berman
Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism
Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment
Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025
FDA Files Corcept's New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
Seegnal Expands Deployment of Seegnal's Prescription Intelligence Platform at Tel Aviv Sourasky Medical Center, a Leading Israeli Public Medical Center and Global Referral Center
Stellar AfricaGold Intersects Multiple Gold-Bearing Zones and Confirms Structural Controls at Tichka Est, Morocco - Drilling Resumed on January 30, 2026
